ArticlePlant biotechnology journal2026
Tonoplast-Localized ABCC Transporters Enhance Heterologous Production of the Antidiabetic Montbretin A and Its Analogues in Nicotiana benthamiana.
Article in Plant biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The plant-derived specialized metabolite montbretin A (MbA) is under development as an improved treatment for Type 2 diabetes, a worldwide epidemic. MbA is an acylated flavonol glycoside so far only found in small amounts in montbretia (Crocosmia × crocosmiiflora) corms. The compound's structural complexity and low natural abundance present major challenges for large-scale production. To enable the development of a scalable MbA production system, we have previously engineered Nicotiana benthamiana to produce MbA. In addition to low levels of MbA, N. benthamiana also produces the pharmaceutically inactive analogues montbretin B and montbretin C, differing from MbA only in their acyl moieties. Follow-up research focusing on precursor engineering has improved MbA yield, but further yield optimization is required to establish N. benthamiana as a scalable MbA production system. Here, we report evidence that transport likely constrains heterologous montbretin production in N. benthamiana and that transporters can be leveraged as bioengineering tools to enhance yield. Specifically, co-expression of tonoplast localized CcABCC4 transporters with montbretin biosynthetic genes in N. benthamiana increased montbretin levels, including those of MbA. Yield increase is likely due to vacuolar sequestration and relies on the presence of an acyl group on the molecule. Eight out of fifteen ABCC4/14 transporters from plant species not known to produce montbretins also enhanced montbretin accumulation in N. benthamiana. These observations suggest that ABCC transporters might be versatile tools for bioengineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.